Kristian Humer was named Principal Accounting Officer of 4D Molecular Therapeutics, Inc. As of November 6, 2026, 4D Molecular Therapeutics, Inc. has reported one leadership change filing to the SEC under Item 5.02 of Form 8-K, on March 30, 2026, naming 1 appointment (Form 8-K, March 30, 2026).
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like 4D Molecular Therapeutics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
4D Molecular Therapeutics, Inc. reported a change among its directors and officers to the SEC on Form 8-K, Item 5.02, on 2026-03-30. It names 1 person. Every row below is cited to the filing it comes from, and this page adds each new change as 4D Molecular Therapeutics, Inc. files it.
Also on the record for 4D Molecular Therapeutics, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| May 15, 2026 | Stake report, Schedule 13G/A, by BVF PARTNERS L P/IL | 9.99% of the class | 5%+ stakes | Source |
| May 15, 2026 | Stake report, Schedule 13G/A, by RA Capital Management, L.P. | 9.9% of the class | 5%+ stakes | Source |
| May 12, 2026 | Stake report, Schedule 13G, by STATE STREET CORPORATION | 5.3% of the class | 5%+ stakes | Source |
| April 7, 2026 | Stake report, Schedule 13G/A, by JANUS HENDERSON GROUP PLC | 10.3% of the class | 5%+ stakes | Source |
| March 26, 2026 | Stake report, Schedule 13G/A, by The Vanguard Group | — | 5%+ stakes | Source |
| February 17, 2026 | Stake report, Schedule 13G, by JANUS HENDERSON GROUP PLC | 8.1% of the class | 5%+ stakes | Source |
| February 17, 2026 | Stake report, Schedule 13G/A, by BVF PARTNERS L P/IL | 9.99% of the class | 5%+ stakes | Source |
| February 17, 2026 | Stake report, Schedule 13G/A, by Novo Holdings A/S | 6.4% of the class | 5%+ stakes | Source |
| February 17, 2026 | Stake report, Schedule 13G/A, by RA Capital Management, L.P. | 9.9% of the class | 5%+ stakes | Source |
| February 9, 2026 | Stake report, Schedule 13G/A, by THE GOLDMAN SACHS GROUP, INC. | 7.5% of the class | 5%+ stakes | Source |
| October 20, 2025 | Stake report, Schedule 13G, by Novo Holdings A/S | 6.8% of the class | 5%+ stakes | Source |
| October 17, 2025 | Stake report, Schedule 13G/A, by BlackRock, Inc. | 6.6% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs 4D Molecular Therapeutics, Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on 4D Molecular Therapeutics, Inc. and the records around it.
4D Molecular Therapeutics, Inc. elsewhere on the record
- 5%+ stake filings May 2026
- Who owns it
Companies that share a holder
- Novo Holdings A/S also filed stake reports on 11 other companies: Avalyn Pharma Inc. (Aug 2026), Hemab Therapeutics Holdings, Inc. (Aug 2026), Obsidian Therapeutics, Inc. (Aug 2026)
- BIOTECHNOLOGY VALUE FUND L P also filed stake reports on 55 other companies: Frazier Life Sciences Acquisition Corp. II (Oct 2026), Olema Pharmaceuticals, Inc. (Oct 2026), Foghorn Therapeutics Inc. (Oct 2026)
- RA Capital Management, L.P. also filed stake reports on 100 other companies: Climb Bio, Inc. (Nov 2026), Bambusa Therapeutics, Inc. (Nov 2026), SOLID BIOSCIENCES INC. (Nov 2026)
Watch 4D Molecular Therapeutics, Inc.
Get an email when 4D Molecular Therapeutics, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on 4D Molecular Therapeutics, Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on 4D Molecular Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on 4D Molecular Therapeutics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
13 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-03-30 | In | Principal Accounting Officer | 8-K, 2026-03-30 |
Who leads 4D Molecular Therapeutics, Inc., as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Principal Accounting Officer: Kristian Humer, appointed (filed 2026-03-30).
New leaders reset buying decisions — get the Full Report on 4D Molecular Therapeutics, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Principal Accounting Officer at 4D Molecular Therapeutics, Inc., with the record behind each one.
Find candidates like Principal Accounting Officer at 4D Molecular Therapeutics, Inc.Every change, in the filing's words
Appointed: Kristian Humer, Principal Accounting Officer
On March 25, 2026, the Board of Directors of 4D Molecular Therapeutics, Inc. (the "Company") appointed Kristian Humer as the Company's Principal Accounting Officer, effective immediately.
- In this role, Mr. Humer succeeds Ashoo Gupta, who continues to serve as the Company's Vice President, Finance and Controller.
- Mr. Humer, age 51, has served as the Company's Chief Financial Officer and Principal Financial Officer since November 2025.
- Mr. Humer previously served as the Chief Financial Officer at Foghorn Therapeutics, Inc., a biotechnology company, from April 2024 to November 2025.
- From July 2021 to September 2023, Mr. Humer served as Chief Financial Officer and Chief Business Officer at Viridian Therapeutics, Inc., a biotechnology company.
- From January 2010 to July 2021, Mr. Humer served in various roles at Citigroup Global Markets Inc., including most recently as Managing Director in the Healthcare Investment Banking Group from December 2016 to July 2021.
- Mr. Humer holds an MBA degree from Duke University's Fuqua School of Business and a BA (Hons) degree in Accounting & Economics from the University of Reading.
Tools for this story
Each opens in a new tab, filled in for 4D Molecular Therapeutics, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.